Durvalumab：無法手術切除的第三期非小細胞肺癌於放射治療合併化療後之鞏固治療

Durvalumab: Consolidation Therapy after Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

10.6880/TJON.201912_19(2).04

關如珺(Ru-Jiun Guan)

durvalumab ； 非小細胞肺癌 ； 免疫檢查點抑制劑 ； 免疫相關不良事件 ； durvalumab ； non-small cell lung cancer ； immune checkpoint inhibitor ； immune-related adverse event

腫瘤護理雜誌

19卷2期（2019 / 12 / 01）

57 - 66

繁體中文

肺癌在全球及台灣都是死亡率最高的癌症，轉移性非小細胞肺癌的治療在過去二十年發展出標靶及免疫藥物後已有很顯著的改善，但在無法手術切除的第三期非小細胞肺癌仍止於使用放射治療合併化療，在此標準治療後給予鞏固化療無法改善整體存活。Durvalumab是作用於PD-L1的免疫治療藥物，藉由阻斷腫瘤細胞的PD-L1與T細胞的PD-1結合，維持T細胞的活性，讓T細胞能夠攻擊腫瘤細胞而達到抗癌的效果，經臨床試驗證實，durvalumab作為無法手術切除的第三期非小細胞肺癌接受放射治療合併化療後疾病未惡化的鞏固治療可顯著改善整體存活，2018年美國食品藥品管理局、歐洲藥品管理局及台灣衛生福利部陸續核准使用。隨著免疫藥物種類、適應症及接受免疫治療的病人逐漸增加，如何處理免疫相關不良事件也是十分重要的課題。

Lung cancer ranks top in cancer-related death worldwide and in Taiwan. The treatment of metastatic non-small cell lung cancer has improved significantly after the development of targeted therapy and immunotherapy in the past two decades. However, concurrent chemoradiotherapy is still the treatment of choice in unresectable stage III non-small cell lung cancer. Consolidation chemotherapy after concurrent chemoradiotherapy does not improve overall survival. Durvalumab is an immunotherapy agent that binds to PD-L1. It blocks the interaction of PD-L1 with PD-1, sustains the activity of T cell, and induces T-cell attack tumor cells to achieve anti-cancer effects. Clinical trials have confirmed that durvalumab, as consolidation therapy, improved overall survival significantly in patients with unresectable stage III non-small cell lung cancer who did not have disease progression after concurrent chemoradiotherapy. The US Food and Drug Administration, the European Medicines Agency, and The Ministry of Health and Welfare in Taiwan have approved its use in 2018. With the increasing types of immunotherapy agents, indications, and patients receiving immunotherapy, how to deal with immune-related adverse events is becoming a very important issue.

1. Ahn, J. S.,Ahn, Y. C.,Kim, J. H.,Lee, C. G.,Cho, E. K.,Chen M.,Park, K.(2015).Multinational randomized phase III trial with or without con-solidation chemotherapy using docetaxel and cisplatin after con-current chemoradiation in inoperable stage III non–small-cell lung cancer: KCSG-LU05-04.Journal of Clinical Oncology,33,2660-2666.
2. Antonia, S. J.,Villegas, A.,Daniel, D.,Vicente, D.,Murakami, S.,Hui, R.,Özgüroğlu, M.(2018).Overall survival with durvalumab after chemo-radiotherapy in stage III NSCLC.The New England Journal of Medicine,379(24),2342-2350.
3. Antonia, S. J.,Villegas, A.,Daniel, D.,Vicente, D.,Murakami, S.,Hui, R.,Özgüroğlu, M.(2017).Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer.The New En-gland Journal of Medicine,377(20),1919-1929.
4. Aupérin, A.,Le Péchoux, C.,Rolland, E.,Curran, W. J.,Furuse, K.,Fournel, P.,Pignon, J. P.(2010).Meta-analysis of concomitant versus sequential radiochemotherapy in locally ad-vanced non-small-cell lung cancer.Journal of Clinical Oncology,28(13),2181-2190.
5. Bezjak, A.,Temin, S.,Franklin, G.,Giaccone, G.,Govindan, R.,Azzoli, C. G.(2015).Definitive and adjuvant radiotherapy in locally advanced non–small-cell lung can-cer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.Journal of Clinical Oncology,33(18),2100-2105.
6. Brahmer, J. R.,Lacchetti, C.,Schneider, B. J.,At-kins, M. B.,Brassil, K. J.,Caterino, J. M.,National Comprehensive Cancer Network(2018).Management of immune-related ad-verse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.Journal of Clinical Oncology,36(17),1714-1768.
7. Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., ... Bray, F. (2018, October 28). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Re-search on Cancer. Retrieved from https://gco.iarc.fr/today
8. Imfinzi (Durvalumab) [package insert]. (2019, Oc-tober 27). European Medicines Agency. Re-trieved from https://www.ema.europa.eu/en/documents/product-information/imfizi-epar-product-information_en.pdf
9. Imfinzi (Durvalumab) [package insert]. (2019, October 27). U.S. Food and Drug Administra-tion. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761069s013lbl.pdf
10. Keytruda (Pembrolizumab) [package insert]. (2019, October 27). U.S. Food and Drug Administra-tion. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s065lbl.pdf
11. Michot, J. M.,Bigenwald, C.,Champiat, S.,Col-lins, M.,Carbonnel, F.,Postel-Vinay, S.,Lambotte, O.(2016).Immune-related adverse events with immune checkpoint blockade: A comprehensive review.European Journal of Cancer,54,139-148.
12. NCCN Clinical Practice Guidelines in Oncolo-gy. Management of immunotherapy-related toxicities. [Version 2.2019]. (2019, October 27). National Comprehensive Cancer Net-work. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf
13. NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer [Version 7.2019]. (2019, October 27). National Comprehensive Cancer Network. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
14. Opdivo (Nivolumab) [package insert]. (2019, Oc-tober 27). U.S. Food and Drug Administra-tion. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s075lbl.pdf
15. Postmus, P. E.,Kerr, K. M.,Oudkerk, M.,Senan, S.,Waller, D.A.,Vansteenkiste, J.,ESMO Guidelines Committee(2017).Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of Oncology,28(Supplement 4),iv1-iv21.
16. Postow, M. A.,Sidlow, R.,Hellmann M. D.(2018).Immune-related adverse events associated with immune checkpoint blockade.The New En-gland Journal of Medicine,378(2),158-168.
17. Puzanov, I.,Diab, A.,Abdallah, K.,Bingham, CO, 3rd,Brogdon, C.,Dadu, R,Society for Im-munotherapy of Cancer Toxicity Management Working Group(2017).Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Journal for Im-munotherapy of Cancer,5(1),95.
18. Tecentriq (Atezolizumab) [package insert]. (2019, October 27). U.S. Food and Drug Administra-tion. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s014lbl.pdf
19. Wanchoo, R.,Karam, S.,Uppal, N. N.,Barta, V. S.,Deray, G.,Devoe, C.,Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors(2017).Adverse renal effects of immune checkpoint inhibitors: A nar-rative review.American Journal of Nephrology,45(2),160-169.
20. 衛生福利部國民健康署（2019，10月22日）．105年癌症登記年報．取自https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=269&pid=10227
21. 衛生福利部統計處（2019，10月25日）．107年度死因統計．取自https://dep.mohw.gov.tw/dos/lp-4472-113.html

1. 謝春金,賴青青,張維允(2023)。一位肺癌個案初次接受免疫治療之護理經驗。腫瘤護理雜誌，23(1)，69-79。